# Rifapentine

## Priftin 150mg (Government)

| TAH Drug Code      | [ORPT](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ORPT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Inactive tuberculosis, With isoniazid in patients with high risk of progression to active disease Tuberculosis,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Dosing             | Adult: in combination with isoniazid 15 mg/kg (rounded up to the nearest 50 or 100 mg; MAX, 900 mg) 25.1-32 kg once a week, Rifapentine 600 mg each time; 32.1-50 kg once a week, Rifapentine 750 mg each time; >50 kg once a week, Rifapentine 900 mg each time (maximum Dose: 900 mg) for 12 weeks. Children: in combination with isoniazid 15 mg/kg (rounded up to the nearest 50 or 100 mg; MAX, 900 mg); 10-14 kg once a week, Rifapentine 300 mg each time; 14.1-25 kg once a week, Rifapentine 450 mg each time; 25.1-32 kg once a week, Rifapentine 600 mg each time; 32.1-50 kg once a week, Rifapentine 750 mg each time; >50 kg once a week, Rifapentine 900 mg each time (maximum dose: 900 mg) for 12 weeks. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Hypersensitivity to rifamycins. concomitant use with rilpivirine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Common Dermatologic: Rash (2.5% to 4.2% ) Gastrointestinal: Clostridium difficile diarrhea Hematologic: Anemia (1.6% to 11.4% ) Hepatic: ALT/SGPT level raised (2.2% to 5% ), AST/SGOT level raised (2.2% to 4.2% ) Immunologic: Lymphocytopenia (3.2% to 10.5% ) Musculoskeletal: Arthralgia (0.9% to 3.6% ) Neurologic: Headache (0.9% to 3% ) Ophthalmic: Conjunctivitis (0.3% to 2.2% ) Respiratory: Hemoptysis (1.9% to 7.5% ) Other: Abnormal color, Red/orange body fluid Serious Hematologic: Neutropenia (6.1% to 8.5% ) Hepatic: Hepatotoxicity Immunologic: Hypersensitivity reaction (Adult, 4%; pediatric, 1.3% )                                                                                            |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

